

Chris Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8381111/publications.pdf>

Version: 2024-02-01

48
papers

2,999
citations

236925
25
h-index

243625
44
g-index

49
all docs

49
docs citations

49
times ranked

4248
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey. Supportive Care in Cancer, 2022, 30, 511-519.	2.2	12
2	Early Outcomes and Decision Regret Using PSMA/MRI-Guided Focal Boost for Prostate Cancer SBRT. Practical Radiation Oncology, 2022, 12, e201-e206.	2.1	8
3	Protocol of DREAM3R: DuRvalumab with chemotherapy as first-line treatment in advanced pleural Mesothelioma—a phase 3 randomised trial. BMJ Open, 2022, 12, e057663.	1.9	9
4	Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region—following radiotherapy. BMC Neurology, 2022, 22, 24.	1.8	2
5	Evaluating the utility of knowledge-based planning for clinical trials using the TROG 08.03 post prostatectomy radiation therapy planning data. Physics and Imaging in Radiation Oncology, 2022, 22, 91-97.	2.9	1
6	Scanxiety: a scoping review about scan-associated anxiety. BMJ Open, 2021, 11, e043215.	1.9	40
7	Experiences with scans and scanxiety in people with advanced cancer: a qualitative study. Supportive Care in Cancer, 2021, 29, 7441-7449.	2.2	12
8	Improving efficiency in the radiation management of multiple brain metastases using a knowledge-based planning solution for single-isocentre volumetric modulated arc therapy (VMAT) technique. Journal of Medical Radiation Sciences, 2021, 68, 364-370.	1.5	2
9	Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation. Radiotherapy and Oncology, 2021, 162, 91-97.	0.6	3
10	Nutritional status and skeletal muscle status in patients with head and neck cancer: Impact on outcomes. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 2187-2198.	7.3	30
11	Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. Strahlentherapie Und Onkologie, 2020, 196, 31-39.	2.0	6
12	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 2020, 21, 1331-1340.	10.7	197
13	Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet, The, 2020, 396, 1422-1431.	13.7	224
14	The Effects of Acupuncture on Cancer-Related Fatigue: Updated Systematic Review and Meta-Analysis. Integrative Cancer Therapies, 2020, 19, 153473542094967.	2.0	30
15	Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1172-1178.	0.8	36
16	Rolling out RapidPlan: What we've learnt. Journal of Medical Radiation Sciences, 2020, 67, 310-317.	1.5	2
17	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncology, The, 2020, 21, 1213-1223.	10.7	109
18	Best Evidence to Best Practice: Implementing an Innovative Model of Nutrition Care for Patients with Head and Neck Cancer Improves Outcomes. Nutrients, 2020, 12, 1465.	4.1	23

#	ARTICLE	IF	CITATIONS
19	Sarcopenia and myosteatosis in patients undergoing curative radiotherapy for head and neck cancer: Impact on survival, treatment completion, hospital admission and cost. <i>Journal of Human Nutrition and Dietetics</i> , 2020, 33, 811-821.	2.5	28
20	Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?. <i>ANZ Journal of Surgery</i> , 2018, 88, 870-875.	0.7	5
21	Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology Oncology</i> , 2018, 1, 531-537.	5.4	106
22	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. <i>European Journal of Cancer</i> , 2015, 51, 352-358.	2.8	40
23	Rates of obstetric intervention and associated perinatal mortality and morbidity among low-risk women giving birth in private and public hospitals in NSW (2000–2008): a linked data population-based cohort study. <i>BMJ Open</i> , 2014, 4, e004551.	1.9	47
24	Risk of recurrence, subsequent mode of birth and morbidity for women who experienced severe perineal trauma in a first birth in New South Wales between 2000 –2008: a population based data linkage study. <i>BMC Pregnancy and Childbirth</i> , 2013, 13, 89.	2.4	34
25	A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, 937-943.	1.2	32
26	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. <i>Lung Cancer</i> , 2013, 81, 422-427.	2.0	51
27	Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2013, 109, 147-153.	6.4	130
28	Trends and risk factors for severe perineal trauma during childbirth in New South Wales between 2000 and 2008: a population-based data study. <i>BMJ Open</i> , 2013, 3, e002824.	1.9	25
29	Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 595-605.	6.3	469
30	Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4701-4708.	3.6	72
31	Rates of obstetric intervention among low-risk women giving birth in private and public hospitals in NSW: a population-based descriptive study. <i>BMJ Open</i> , 2012, 2, e001723.	1.9	93
32	Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. <i>Annals of Oncology</i> , 2012, 23, 2020-2027.	1.2	39
33	CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. <i>British Journal of Cancer</i> , 2012, 106, 633-637.	6.4	36
34	Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. <i>British Journal of Cancer</i> , 2012, 107, 588-591.	6.4	170
35	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. <i>Annals of Oncology</i> , 2012, 23, 1185-1189.	1.2	57
36	Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergruop (GCIG) CALYPSO sub-study. <i>Annals of Oncology</i> , 2011, 22, 2417-2423.	1.2	49

#	ARTICLE	IF	CITATIONS
37	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 2011, 103, 1338-1342.	6.3	33
38	Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 2011, 105, 1144-1150.	6.4	32
39	Carboplatin+paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 2011, 105, 360-365.	6.4	28
40	Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.. Journal of Clinical Oncology, 2011, 29, 5052-5052.	1.6	8
41	Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Society, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, London, Ont. Sept. 15-18, 2011.. Canadian Journal of Surgery, 2011, 54, S57-S104.	1.2	0
42	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology, 2010, 28, 3323-3329.	1.6	500
43	ABC; An AGITG trial of fixed dose rate (FDR) gemcitabine (gem) and cisplatin for patients (pts) with advanced biliary tract cancer (ABC). Journal of Clinical Oncology, 2007, 25, 15015-15015.	1.6	0
44	Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 2006, 107, 4623-4627.	1.4	32
45	A Prospective Phase II Comparison of Stem Cell Source Using Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) RE+Induction, Then High Dose Fludarabine, Busulfan (FLUBU) and Autologous (ASCT) or Allogeneic (AlloSCT) Hematopoietic Blood Stem Cell Transplantation for Mantle Cell (MCL) and Relapsed Low-Grade B-Cell Non-Hodgkin+Lymphoma (NHL).. Blood, 2004, 104, 915-915.	1.4	0
46	A Low CD34+ Cell Dose Predicts Relapse and Death Early following Autologous Blood Stem Cell Transplantation. Hematology, 2001, 6, 19-27.	1.5	5
47	Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplantation, 1999, 23, 111-117.	2.4	46
48	High-level expression of secreted glycoproteins in transformed lepidopteran insect cells using a novel expression vector. , 1998, 60, 656-663.		86